Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 18.05.2026 1 Am J Clin Pathol 1 Am J Surg Pathol 2 BJU Int 1 BMC Cancer 1 BMC Urol 2 Br J Cancer 1 Clin Cancer Res 1 Eur Radiol 3 Eur Urol 1 Int J Urol 2 J Urol 2 Magn Reson Med 1 Nat Rev Urol 2 PLoS One 4 Prostate

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. SALEHI M, Alaee M, Mousavi M, Panahi G, et al
   Salivary and serum microRNAs as noninvasive biomarkers for distinguishing prostate cancer from benign prostatic hyperplasia.
   Am J Clin Pathol. 2026;165:aqag028.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

2. NGUYEN NJ, Castillo VF, Olkhov-Mitsel E, Saleeb RM, et al
   The Value of Systematic Versus Targeted Sampling in Prostate Cancer Detection and the Identification of Adverse Pathologic Features: A Retrospective Review of Over 1400 Combined Prostate Biopsies.
   Am J Surg Pathol. 2026 May 11. doi: 10.1097/PAS.0000000000002564.
   PubMed         Abstract available
   
   

   
   BJU Int

3. CALPIN GG, Hehir CM, Alzayer M, MacCurtain BM, et al
   Transrectal vs transperineal prostate biopsy: a systematic review and meta-analysis.
   BJU Int. 2026;137:958-967.
   PubMed         Abstract available
   
   
4. WEI N, Phillips RM, Kwon E, Stish BJ, et al
   Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial.
   BJU Int. 2026 May 12. doi: 10.1111/bju.70305.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. SCHIESS R, Athanasiou A, Kasten MME, Hansen TF, et al
   Proclarix' performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish population.
   BMC Cancer. 2026 May 9. doi: 10.1186/s12885-026-16118.
   PubMed         Abstract available
   
   

   
   BMC Urol

6. JIANG S, Zheng X, Qiu H, Tao N, et al
   The low-grade Inflammation Score (INFLA-Score) as a predictor of overall survival in prostate cancer: a UK biobank cohort study.
   BMC Urol. 2026 May 8. doi: 10.1186/s12894-026-02078.
   PubMed         Abstract available
   
   

   
   Br J Cancer

7. WALDRON NR, Silva D, Westaby D, Jimenez-Vacas J, et al
   Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities.
   Br J Cancer. 2026 May 13. doi: 10.1038/s41416-026-03441.
   PubMed         Abstract available
   
   
8. YANG K, Thong MSY, Doege D, Koch-Gallenkamp L, et al
   Diabetes mellitus and health-related quality of life in long-term survivors of breast, colorectal or prostate cancer: a population-based prospective study.
   Br J Cancer. 2026 May 13. doi: 10.1038/s41416-026-03463.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

9. YANG DD, Abdelnaser A, Haas AJ, Wala J, et al
   Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.
   Clin Cancer Res. 2026 May 11. doi: 10.1158/1078-0432.CCR-25-4900.
   PubMed         Abstract available
   
   

   
   Eur Radiol

10. MAKWANA R, Esengur OT, Turkbey B
    Reproducibility analysis to support prostate MRI-informed care: independent validation of risk-stratified PSA density thresholds for clinically significant prostate cancer.
    Eur Radiol. 2026 May 13. doi: 10.1007/s00330-026-12556.
    PubMed        
    
    

    
    Eur Urol

11. DE LAERE B, Mortezavi A, Eklund M, Gronberg H, et al
    Letter to the Editor: Advanced and Metastatic Prostate Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up.
    Eur Urol. 2026 May 14:S0302-2838(26)02148-2. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
12. CAVKA L, Nandakumar S, Wu Q, Mehta NJ, et al
    IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.
    Eur Urol. 2026 May 13:S0302-2838(26)02049-X. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
13. MEIER RM, Aghdam N, Beckman AC, Woodhouse SA, et al
    10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial.
    Eur Urol. 2026 May 8:S0302-2838(26)02153-6. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    

    
    Int J Urol

14. KYODA Y, Hori M, Nakanishi M, Shindo T, et al
    Impact of Hormonal and Radiation Therapy on Bladder Outlet Obstruction in High-Risk Localized Prostate Cancer: A Prospective Pressure-Flow Study.
    Int J Urol. 2026;33:e70502.
    PubMed         Abstract available
    
    

    
    J Urol

15. CAMPBELL JA, Su ZT, Pavlovich CP
    Diet, Exercise, and Risk of Prostate Cancer Progression: Current Evidence in Active Surveillance.
    J Urol. 2026 May 13:101097JU0000000000005116. doi: 10.1097/JU.0000000000005116.
    PubMed        
    
    
16. WHITNEY DH, Clay M, Wipperfurth J, Wylie D, et al
    Semen RNA-Based Biomarkers for Prostate Cancer Detection and Risk Stratification: A Prospective Multi-Center Validation Study.
    J Urol. 2026 May 13:101097JU0000000000005123. doi: 10.1097/JU.0000000000005123.
    PubMed         Abstract available
    
    

    
    Magn Reson Med

17. PHIPPS A, Kurniawan ND, Watson G, Sved P, et al
    Characterizing the Diffusion Properties of Prostate Tissue Using Paired MR Microscopy and Multidimensional Diffusion MRI.
    Magn Reson Med. 2026;96:349-365.
    PubMed         Abstract available
    
    
18. TAMADA D, Pirasteh A, Jarrard DF, Hernando D, et al
    Quantitative Diffusion and T2 Mapping Using RF-Modulated Phase-Based Gradient Echo Imaging.
    Magn Reson Med. 2026;96:49-65.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

19. WANG Z, Gu B, Sharkey C, Ge R, et al
    SRD5A2 and emerging therapies in androgen-driven disorders.
    Nat Rev Urol. 2026;23:319-332.
    PubMed         Abstract available
    
    

    
    PLoS One

20. WANG Y, Feng L, He L, Liu N, et al
    [(1)(8)F]PSMA-1007 PET/CT in biochemical recurrence after radical prostatectomy: A single-center experience of detection rate and lesion distribution.
    PLoS One. 2026;21:e0349397.
    PubMed         Abstract available
    
    
21. HAMILTON RA, Paul B, Yi P, Rajapakshe K, et al
    Identification of CAND1 as a DNA-dependent protein kinase-regulated coactivator of androgen receptor and the ARv7 splice variant.
    PLoS One. 2026;21:e0349130.
    PubMed         Abstract available
    
    

    
    Prostate

22. SHUKLA S, McGrath J, Willis R, Venkatesh A, et al
    Protein Kinase D1 Translocates PARP1 to the Membrane and Is Associated With Increased Sensitivity to Cell Viability Inhibition by PARP1 Inhibitor Olaparib.
    Prostate. 2026;86:1091-1100.
    PubMed         Abstract available
    
    
23. RAVIZZINI PIC, Delmonte LF, Valdo VAG, Rangel DA, et al
    Challenging the Evolving Nomenclature of Ultrasound-Guided Transperineal Prostate Biopsy: A Call for Standardization.
    Prostate. 2026;86:975-981.
    PubMed         Abstract available
    
    
24. TASKIRAN AT, Senoglu Y
    Is Saturation Biopsy Still a Viable Alternative to Fusion Biopsy in the Era of Multiparametric MRI? A Comparative Analysis in Patients With Prior Negative Biopsy.
    Prostate. 2026;86:990-996.
    PubMed         Abstract available
    
    
25. LUK JTF, Lin AH, Cheung EKC, Mecani R, et al
    Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta-Analysis of a Potential Therapeutic Target.
    Prostate. 2026;86:1061-1068.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum